

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: AP2/22 - Antithrombotic Agents

Deadline: 16.09.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban					31							31	30	97%
Samples and groups	[µg/L]													
Sample A1		74,5	9,3	13	31	CVP	74,5	4,1	25%	55,8	93,2	31	30	97%
(38) IL		82,3	2,2	2,7	10	0						10		
(94) Stago		69,0	5,9	8,6	6	0						6		
(149) Siemens (Dade, BN, Dimension)		78,0	3,0	3,8	5	0						5		
(193) HYPHEN BioMed		67,7	6,2	9,2	7	0						7		
Other					3	0						3		
Sample B1		294	21	7,2	31	CVP	294	9,3	25%	220	368	31	31	100%
(38) IL		306	7,3	2,4	10	0						10		
(94) Stago		304	14	4,6	6	0						6		
(149) Siemens (Dade, BN, Dimension)		302	18	6,0	5	0						5		
(193) HYPHEN BioMed		267	28	11	7	0						7		
Other					3	0						3		
Set 2														
(109) Dabigatran					34							34	30	88%
Samples and groups	[µg/L]													
Sample A2		44,8	5,4	12	34	CVP	44,8	2,3	25%	33,6	56	34	30	88%
(38) IL		47,5	2,3	4,9	12	0						12		
(149) Siemens (Dade, BN, Dimension)		40,0	5,9	15	8	0						8		
(193) HYPHEN BioMed		46,1	7,6	16	11	0						11		
Other					3	0						3		
Sample B2		223	22	10	34	CVP	223	9,4	25%	167	279	34	33	97%
(38) IL		217	19	8,6	12	0						12		
(149) Siemens (Dade, BN, Dimension)		208	10	5,0	8	0						8		
(193) HYPHEN BioMed		247	23	9,2	11	0						11		
Other					3	0						3		
Set 3														
(110) Rivaroxaban					38							38	37	97%
Samples and groups	[µg/L]													
Sample A3		73,0	6,3	8,6	38	CVP	73	2,5	25%	54,7	91,3	38	37	97%
(38) IL		75,0	6,4	8,5	12	0						12		
(94) Stago		68,7	2,0	2,9	6	0						6		
(149) Siemens (Dade, BN, Dimension)		70,0	4,4	6,4	5	0						5		
(179) Siemens		75,5	3,7	4,9	5	0						5		
(193) HYPHEN BioMed		73,2	3,6	5,0	9	0						9		
Other					1	0						1		
Sample B3		299	28	9,4	38	CVP	299	11	25%	224	374	38	38	100%
(38) IL		278	14	5,0	12	0						12		
(94) Stago		303	9,3	3,1	6	0						6		
(149) Siemens (Dade, BN, Dimension)		305	24	8,0	5	0						5		
(179) Siemens		310	32	10	5	0						5		
(193) HYPHEN BioMed		317	13	3,9	9	0						9		
Other					1	0						1		

st_kn_p

End of report

Printed: 21.09.2022